Sam Straw

Predicting one-year mortality in heart failure using the 'Surprise Question': a prospective pilot study.

Heart failure: A preventable and treatable complication of type 2 diabetes.

Long-term Outcomes Are Poor in Intravenous Drug Users Following Infective Endocarditis, Even After Surgery.

Futility in cardiology: the need for a change in perspectives: reply.

Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study.

Infection-Related Hospitalization in Heart Failure With Reduced Ejection Fraction: A Prospective Observational Cohort Study.

Comparison of quantity and quality of muscle as clinical prognostic markers in patients undergoing carotid endarterectomy.

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus.

Dying 'due to' or 'with' COVID-19: a cause of death analysis in hospitalised patients.

Prioritizing symptom management in the treatment of chronic heart failure.

Observational data during the COVID-19 pandemic: opportunity with uncertainty.

Unique Transcriptome Signature Distinguishes Patients With Heart Failure With Myopathy.

Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction.

Secondary mitral regurgitation: reducing the leak, expanding the science.

Association of heart failure and its comorbidities with loss of life expectancy.

Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".

Closing the loop: Delivering personalised care for patients with cryptogenic stroke.

Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence.

Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data.

To the Editor-New phones, old problem? Interference with cardiovascular implantable electronic devices by phones containing magnets.

Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study.

Quantifying the relationship and contribution of mitochondrial respiration to systemic exercise limitation in heart failure.

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.

Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study.

Impact of the COVID-19 pandemic on the management of chronic heart failure.

Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure.

Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity?

We Do Not Talk to Patients About Their Prognosis, But Is Any of This Surprising?

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.

Heart rate, exercise capacity, and the force-frequency relationship in chronic heart failure.

Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial.

An enormous right atrial myxoma highlights the role of echocardiography in heart failure pathways: a case report.

Diabetes mellitus and the causes of hospitalisation in people with heart failure.

Cardiac resynchronisation therapy with or without a defibrillator: individualising device prescription.

Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?

Surgical Techniques and Outcomes in Patients With Intra-Cardiac Abscesses Complicating Infective Endocarditis.

Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.

Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure.

Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes.

'Acute Heart Failure': Should We Abandon the Term Altogether?

Clinical implications and risk factors for QRS prolongation over time in heart failure patients.

Correction: Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data.

Improving the management of left ventricular thrombus in a tertiary cardiology centre: a quality improvement project.

Remote monitoring in heart failure: it's the data you collect what you do with them.

Atrial secondary mitral regurgitation: prevalence, characteristics, management, and long-term outcomes.

Relationship Among Diabetes, Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort Study.

Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis.

Outcomes following cardiac resynchronisation therapy in older people.

Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction.